



**CUMBERLAND**<sup>®</sup>  
PHARMACEUTICALS

Corporate Presentation

Nasdaq CPIX

# Safe Harbor Statement

---

This presentation contains forward-looking statements concerning our approved products and product development, our technology, our competitors, our intellectual property, our financial condition and our plans for research and development programs that involve risks, uncertainties and assumptions. These statements are based on the current estimates and assumptions of the management of Cumberland Pharmaceuticals as of the date of this presentation and are subject to uncertainty and changes in circumstances. Given these uncertainties, you should not place undue reliance upon these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties, assumptions and other factors that may cause the actual results of Cumberland Pharmaceuticals to be materially different from those reflected in such forward-looking statements.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, those set forth under the headings "Risk factors" and "Management's discussion and analysis of financial condition and results of operations" in our Form 10-K and Form 10-Q Reports on file with the SEC. The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. All statements contained in this presentation are made only as of the date of this presentation. For more information on our brands, including full prescribing and safety information, please see the links to the product websites which can be found at [www.cumberlandpharma.com](http://www.cumberlandpharma.com).



# Nation's Health Care Capital

# NASHVILLE

## The Nation's Health Care Industry Capital

### NASHVILLE HEALTH CARE COUNCIL

Globally, Nashville's health care industry generates more than \$70 billion in revenue and 400,000 jobs each year.

Fifteen publicly traded health care companies are headquartered in Nashville.

Nashville is a diverse health care hub with growth sectors including ambulatory and outpatient surgery, long-term care, academic research, hospital management, health information technology, and life sciences.

Home to a dynamic community of more than 250 health care companies, Nashville remains a one-of-a-kind center of innovation in the U.S., with a worldwide impact on the industry landscape. Since 1995, the Nashville Health Care Council has helped the nation's premier health care industry hub thrive.

[www.healthcarecouncil.com](http://www.healthcarecouncil.com)



# Company Overview

**Specialty pharmaceutical** company

Portfolio of FDA approved **branded** products

Promoted by **three** national sales divisions

Several **catalysts** for new growth opportunities

**Sancuso**<sup>®</sup> post-acquisition integration and market expansion

Next Generation **Caldolor**<sup>®</sup> product with **expanded labeling**

**Vibativ**<sup>®</sup> acute care, out-patient and international initiatives

**Phase II candidates** in development with study results milestones

Proven record of successful **product development** and product **acquisition**



# Mission & Strategy

---

**Mission:** Working together to provide unique products that improve the quality of patient care

---

**Strategy:** We are building a portfolio of *specialized biopharmaceutical brands*



# Product Portfolio

Product  
Development:

**IV** **ACETADOTE**<sup>®</sup>

**CALDOLOR**<sup>®</sup>


Product  
Acquisition:

 **KRISTALOSE**<sup>®</sup>

 **VIBATIV**<sup>®</sup>  
(telavancin) for injection

 **Vaprisol**<sup>®</sup>

**Sancuso**<sup>®</sup>  
(Granisetron Transdermal System)

 **Talicia**<sup>®</sup>  
(omeprazole magnesium,  
amoxicillin, and rifabutin)



# IV ACETADOTE®

- IV treatment for **America's leading cause of poisoning**
- **Treats liver toxicity** associated with acetaminophen overdose
- Acetadote (IV N-Acetylcysteine) **developed** and **registered** by Cumberland
- IV N-Acetylcysteine now **standard of care**
- Cumberland developed **unique EDTA free formulation**
- **New dosing** regimen approved with **FDA exclusivity**



*\*National Poison Data System, American Association of Poison Centers*



**CALDOLOR**<sup>®</sup>  
*(ibuprofen) Injection*



**CALDOLOR**<sup>®</sup>  
*(ibuprofen) Injection*


Your **Non-Opioid** Pain  
Management Solution<sup>1</sup>



# CALDOLOR®

- **Injectable** delivery of **ibuprofen**
- **Developed** and **registered** by Cumberland
- **Antipyretic, analgesic & anti-inflammatory** properties
- Evaluated in **published studies** with ~ **2,000 patients**
- **Approved** for use in **adults, children** and **newborns**
- **Prior to surgery** administration approved by FDA
- New data with **favorable comparison to ketorolac**
- **Recent publication** featuring profile **in geriatric patients**

\*





**KRISTALOSE<sup>®</sup>**  
(lactulose) For Oral Solution

**freedom  
to go** with  
Kristalose






# KRISTALOSE<sup>®</sup>

(lactulose) For Oral Solution

- **Unique** crystalline formulation of lactulose
- Prescription strength laxative
- **Clinically proven** increase in patient satisfaction
- Featured in **award winning** marketing campaign
- Supported by key **co-promotion partners**
- **New initiatives** underway to **protect and grow** business




 **VIBATIV**<sup>®</sup>  
(telavancin) for injection



**VIBATIV**<sup>®</sup>  
(telavancin) for inject


**VIBATIV**  
**WHEN YOUR NEXT STEP IS CRITICAL**

The once-daily antibiotic infusion with a dual mechanism of action indicated for MRSA and MSSA

 **CUMBERLAND**<sup>®</sup>  
PHARMACEUTICALS



- IV antibiotic that treats **life-threatening infections**
- **Potent treatment** for pneumonia and serious skin infections resulting from gram positive bacteria
- Used in **hospital acute care** and **out-patient center** settings
- Unique ability to **penetrate tissues**
- Product features **favorable resistance profile**
- Growing **international approvals and opportunity**



# Sancuso<sup>®</sup>

(Granisetron Transdermal System)

## ONLY Sancuso<sup>®</sup>

(Granisetron Transdermal System)

Keeps them covered



Prevention  
of CINV<sup>1</sup>

CINV=chemotherapy-induced nausea and vomiting

#### Indications and Usage

SANCUSO (granisetron transdermal system) is indicated for the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days.

#### Important Safety Information


##### Contraindications

SANCUSO is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the transdermal system.

Please see additional Important Safety Information throughout and full Important Safety Information on page 8. See accompanying full Prescribing Information.





 **Talicia**<sup>®</sup>  
(omeprazole magnesium,  
amoxicillin, and rifabutin)

*Convenience of*  
**UNIQUE ALL-IN-ONE-FORMULATION**

Talicia<sup>®</sup> is indicated for the treatment of  
***Helicobacter pylori*** stomach infections in adults  
*The leading risk factor for gastric cancer*

- High *H. pylori* eradication rates regardless of resistance
- Clarithromycin-free formulation
- Only *H. pylori* treatment with a warranty program



# Talicia®

(omeprazole magnesium,  
amoxicillin, and rifabutin)

- FDA-approved oral capsule for the **treatment of *Helicobacter pylori* (*H. pylori*)** infection in adults, a bacterial infection of the stomach and leading risk factor for gastric cancer
- A fixed-dose, **all-in-one capsule** combination of two antibiotics, **amoxicillin** and **rifabutin**, and a proton pump inhibitor, **omeprazole**
- Patented, and a **first line treatment**



# Ifetroban Overview

---

- Cumberland's first **new chemical entity**
- A **potent, selective** antagonist of thromboxane receptor
- Discovered and initially developed by Bristol-Myers Squibb
- **Safety well-established** in 30 clinical studies with **over 1,400 subjects**
- Collaborating with **Vanderbilt, Harvard, Scripps** and other academic centers
- Successfully manufactured **both IV** and **oral formulations**



# Ifetroban Development Pipeline



**Dyscorban<sup>®</sup>** (*Duchenne muscular dystrophy*)

**Vasculan<sup>®</sup>** (*Systemic sclerosis*)

**Fibroban<sup>®</sup>** (*Idiopathic Pulmonary Fibrosis*)



# Duchenne Muscular Dystrophy (DMD)

---

- **A rare, fatal, neuromuscular disease** with the progressive loss of muscle resulting in deterioration of the skeleton, heart and lungs
- Cumberland is investigating ifetroban for the treatment of **cardiomyopathy** that is associated with DMD
- **Preclinical data** demonstrates ifetroban could prevent cardiac fibrosis and improve cardiac function – published **Journal American Heart Association**
- The **FDA** has awarded over \$1 million in **Orphan Drug Grant** funding
- **Orphan Drug** and **Rare Pediatric Disease** Designations approved
- **Phase II study** completed with **breakthrough results** announced
- **Fast Track** Designation also approved!



# Systemic Sclerosis (SSc)


---

- Debilitating, **chronic autoimmune disease** causing thickening of the skin and fibrosis of internal organs
- **Highest death rate** of any rheumatic condition
- Average **survival** is approximately **11 years** from diagnosis
- **Women** more commonly affected; also occurs in **children**
- No FDA approved treatment for this **unmet medical need**
- **Phase II study** enrollment completed
- **Top line study results** to be reported next



# Fibroban® in IPF

- Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) are a group of disorders that causes irreversible scarring (fibrosis) of lung tissue that leads to lung function decline and early mortality
- Idiopathic **Pulmonary Fibrosis** (IPF) is the most common form of PF-ILDs
- **Orphan disease**
- IND cleared and **Phase II study** is well underway





- **Joint initiative** to build **long term pipeline**
- Collaborating with **Academic Research** Partners
- Building **portfolio** of innovative **biopharmaceutical candidates**
- Supporting product development through **grant initiatives**
- Managing Nashville's **Life Science Center**
- Houses **Cumberland's formulation** and **testing laboratories**



# Building a Diversified Product Portfolio



**Deploying a Multifaceted Strategy to Create Value**



# Commercial Portfolio Expansion Strategy



## EXPAND

*Existing Products*



## DEVELOP

*Early-Stage Candidates*



## IDENTIFY

*Late Stage Candidates*



## ACQUIRE

*Under-Promoted,  
Approved Brands*

**PRODUCT  
PORTFOLIO**



# Acquisition Initiative



**GOAL TO ADD ONE NEW PRODUCT PER YEAR**

through business development initiative or internal product development



Active, ongoing initiative to identify, evaluate and acquire/license **new products** into the portfolio



Source opportunities through direct efforts and intermediaries



Seek commercial and late stage development assets that fit our **strategy and focus**

- Branded, Rx products in hospital acute care gastroenterology or oncology
- Sales of **\$5-25 million** with attractive margins and differentiated features



# Income Statement

(\$ IN MILLIONS)

FY 2025

Net Revenues	\$ 44.5
Cost of Products Sold	<u>6.7</u>
Gross Profit	37.8
Selling & Marketing	19.1
Research & Development	5.6
General Administrative	11.6
Amortization	4.0
Adjusted Earnings	2.1
Cash flow from operations	<u>4.9</u>



# Summary Balance Sheet

*(\$ in millions)*

Dec 31, 2025

Cash and Securities

\$11

Total Assets

77

Total Liabilities

52

Total Equity

25

Total Liabilities and Equity

\$77

*\*tax carryforward credits of \$54 million available*



# Cumberland Moving Forward



Diverse product portfolio of **FDA approved brands**



Proven **development and commercialization** capabilities



Various initiatives in place to support **near-term growth**



**Phase II** products in development with study results milestones



**Valuation gap** given level of sales, assets, infrastructure and pipeline





**CUMBERLAND<sup>®</sup>**  
PHARMACEUTICALS

NASDAQ: CPIX